Adjuvant chemotherapy with mFOLFOXIRI versus mFOLFOX6 in MRD-positive stage II-III colorectal cancer

被引：0
|
作者：
Zhang, Jianwei
Hu, Huabin
Cai, Yue
Xie, Xiaoyu
Wu, Zehua
Ling, Jiayu
Chen, Dianke
Liu, Ping
Kang, Liang
Deng, Yanhong
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
[3] Kunming Med Univ, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China
[4] Sun Yat Sen Univ, Dept Colorectal Surg, Affiliated Hosp 6, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3642
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study)
    Kosugi, Chihiro
    Koda, Keiji
    Ishibashi, Keiichiro
    Yoshimatsu, Kazuhiko
    Tanaka, Soichi
    Kato, Ryouji
    Kato, Hiroyuki
    Oya, Masatoshi
    Narushima, Kazuo
    Mori, Mikito
    Shuto, Kiyohiko
    Ishida, Hideyuki
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2018, 33 (06) : 809 - 817
  • [12] Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer:: a multicentre randomised controlled phase III trial
    Nordlinger, B
    Rougier, P
    Arnaud, JP
    Debois, M
    Wils, J
    Ollier, JC
    Grobost, O
    Lasser, P
    Wals, J
    Lacourt, J
    Seitz, JF
    dos Santos, JG
    Bleiberg, H
    Mackiewickz, R
    Conroy, T
    Bouché, O
    Morin, T
    Baila, L
    van Cutsem, E
    Bedenne, L
    LANCET ONCOLOGY, 2005, 6 (07): : 459 - 468
  • [13] mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
    Zhang, J.
    Deng, Y.
    Wu, Z.
    Hu, H.
    Cai, Y.
    Ling, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [14] mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A propensity score analysis from two prospective trials
    Zhang, J.
    Hu, H.
    Wu, Z.
    Cai, Y.
    Ling, J.
    Xiao, J.
    Deng, Y-H.
    ANNALS OF ONCOLOGY, 2018, 29 : 28 - 28
  • [15] AS SURGICAL ADJUVANT CHEMOTHERAPY FOR STAGE II AND III COLORECTAL CANCER
    Ogawa, Masaichi
    Hada, Takenori
    Kobayashi, Tetsuya
    Eto, Ken
    Hayashi, Takenori
    Mitsuyama, Nobuyoshi
    Okuma, Masanao
    Iida, Naoko
    Kashiwagi, Hideyuki
    Yanaga, Katsuhiko
    ANNALS OF ONCOLOGY, 2011, 22 : v94 - v94
  • [16] Adjuvant FOLFOX Chemotherapy and Splenomegaly in Patients with Stages II-III Colorectal Cancer
    Angitapalli, Revathi
    Litwin, Alan M.
    Kumar, Prasanna R. G.
    Nasser, Eiad
    Lombardo, Jeffrey
    Mashtare, Terry
    Wilding, Gregory E.
    Fakih, Marwan G.
    ONCOLOGY, 2009, 76 (05) : 363 - 368
  • [17] Role of adjuvant chemotherapy in patients with stage II-III ampullary cancer.
    Semenov, Nikolay
    Zhukova, Lyudmila
    Grechukhina, Katerina
    Izrailov, Roman
    Dalgatov, Kamil
    Khatkov, Igor
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 508 - 508
  • [18] M6A-BASED BIOMARKERS FOR RISK-STRATIFICATION AND RESPONSE PREDICTION TO ADJUVANT CHEMOTHERAPY IN STAGE II-III COLORECTAL CANCER
    Sui, Silei
    Xu, Caiming
    Castells, Antoni
    Balaguer, Francesc
    Bujanda, Luis
    Goel, Ajay
    GASTROENTEROLOGY, 2023, 164 (06) : S990 - S990
  • [19] BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
    Benson, Al B., III
    Kiss, Igor
    Bridgewater, John
    Eskens, Ferry A. L. M.
    Sasse, Carolyn
    Vossen, Sandra
    Chen, Jihong
    Van Sant, Chip
    Ball, Howard A.
    Keating, Anne
    Krivoshik, Andrew
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5058 - 5067
  • [20] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
12345